Clinical trials
Membranous Nephropathy clinical trials
Below are recruiting membranous nephropathy clinical trials, each written for real people, not researchers. We’re tracking 37 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03929887Recruiting
Kidney biopsy patients join a kidney tissue research bank
This study builds a kidney tissue “library” to help researchers analyze kidney disease in newer ways. It may help by improving how glomerular (kidney filter) diseases are understood over time, using samples from people who already had a biopsy.
ChuncheonAges Any age - NCT06466135RecruitingPhase 2
Study of WAL0921 for glomerular kidney diseases
This study tests a new drug called WAL0921 for people with certain types of kidney disease. The goal is to see if it can help protect kidney function.
Los Angeles, CaliforniaAges 18–75 - NCT00977977RecruitingPhase 2
Rituximab plus cyclosporine for membranous kidney disease
This trial tests whether rituximab (an immune-targeting medicine) plus cyclosporine (another immune medicine) can better control protein leakage in the urine for people with idiopathic membranous nephropathy. It may help reduce long-lasting kidney damage risk when standard treatments like ACE inhibitor or ARB don’t control the protein level.
Bethesda, MarylandAges 18–90 - NCT05505500Recruiting
Parent and patient interviews for childhood kidney swelling
This study uses interviews to understand how swelling from nephrotic syndrome affects daily life for children and their caregivers. It may help researchers design better care by capturing the patient and parent perspective.
Ann Arbor, MichiganAges 2 years+ - NCT07571746RecruitingPhase 2
Surovatamig for antibody-mediated kidney disease
This study tests a new medicine called surovatamig for adults with a specific type of kidney disease caused by the body's own antibodies (anti-PLA2R antibody-positive membranous nephropathy). The medicine may help reduce kidney damage and improve kidney function.
Los Angeles, CaliforniaAges 18–75 - NCT06893328Recruiting
Real-world study of primary membranous nephropathy
This study looks at how well a treatment works for people with primary membranous nephropathy (PMN), a kidney condition. It is meant for patients who still have high protein in their urine despite taking standard blood pressure medicines.
Guangzhou, GuangdongAges 18 years+ - NCT04571658Recruiting
NEPTUNE Match study linking you to possible kidney research trials
This study is an add-on process that uses information from the NEPTUNE kidney study to see whether you might be able to join other kidney research trials. It may help connect eligible people with appropriate new treatment studies when they become available.
Atlanta, GeorgiaAges 1–80 - NCT04745728RecruitingPhase 3
Testing different immune-suppressing treatments for membranous kidney disease
This Phase 3 trial compares different immune-suppressing medicines for idiopathic membranous nephropathy (a kidney disease caused by the immune system). It may help reduce heavy protein leakage in the urine and improve disease control in people who fit specific prior-treatment and lab requirements.
Beijing, Beijing MunicipalityAges 18–80 - NCT06557265RecruitingPhase 1/Phase 2
NKX019 for lupus kidney disease or membranous nephropathy
This trial tests an experimental cell therapy called NKX019 for people with active lupus nephritis (a type of kidney inflammation from lupus) or primary membranous nephropathy (another kidney condition) that hasn't gotten better after standard treatments. It may help if you have tried at least two treatments for lupus kidney disease or one for membranous nephropathy and still have active kidney disease.
Little Rock, ArkansasAges 18–75 - NCT06285279RecruitingPhase 1
CAR-T cell therapy for hard-to-treat autoimmune kidney diseases
This trial tests a new type of cell therapy called CAR-T cells that target two proteins (BCMA and CD19) to treat autoimmune kidney diseases that are not responding to standard treatments. The goal is to see if this therapy can help control the disease and improve kidney function.
Nanjing, JiangsuAges 18–65 - NCT07038382RecruitingPhase 2
Study of HLX79 with Rituximab for Active Kidney Disease
This trial tests a new drug called HLX79 (a human sialidase fusion protein) combined with rituximab, compared to a placebo, for people with active membranous nephropathy (a kidney disease). It aims to see if this combination can reduce protein in the urine and improve kidney function.
BeijingAges 18–75 - NCT01209000Recruiting
Study for children with new kidney protein loss
This study is for children (and some newly diagnosed patients) who have nephrotic syndrome—kidneys leaking a lot of protein. It aims to better understand the kidney condition (sometimes using biopsy) and support future care decisions.
Los Angeles, CaliforniaAges Up to 80 years - NCT07516964Recruiting
Studying autoimmune kidney disease in children and adults
This study collects medical information and samples from patients with podocytopathy—a type of autoimmune kidney disease that causes protein leakage into urine. Researchers will analyze your medical records and any blood or kidney tissue samples you've already had to better understand the disease and find better treatments.
Rochester, MinnesotaAges birth–99 years
Hear when a new Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for membranous nephropathy?
- Yes. Clin2 currently lists 37 recruiting membranous nephropathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a membranous nephropathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a membranous nephropathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.